apa pentru preparate injectabile
zentiva s.a. - romania - diverse - solv. pt. uz parent. - preparate fara actiune terapeutica solventi si agenti pentru dilutii, incl. sol. pentru irigare
xarelto
bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - agenți antitrombotici - xarelto, administrat concomitent cu acidul acetilsalicilic (aas) singur sau cu asa plus clopidogrel sau ticlopidina, este indicat pentru prevenirea evenimentelor aterotrombotice la pacienții adulți după un sindrom coronarian acut (sca) cu valori crescute biomarkerii cardiaci. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenți antitrombotici - prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 pentru haemodynamically instabil pe pacienți). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 și 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenți antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
ser fiziologic 9 mg/ml
antibiotice s.a. - romania - natrii chloridum - solv. pt. uz parent. - 9mg/ml - preparate fara actiune terapeutica solventi agenti pentru dilutii
urapidil kalceks 25 mg
as kalceks - letonia - urapidilum - sol. inj./perf. - 25mg - antiadrenergice antagonisti ai receptorilor alfa-adrenergici
urapidil kalceks 50 mg
as kalceks - letonia - urapidilum - sol. inj./perf. - 50mg - antiadrenergice antagonisti ai receptorilor alfa-adrenergici
vasonit comprimate filmate cu eliberare prelungita 600 mg
lannacher heilmittel gmbh - pentoxifyllinum - comprimate filmate cu eliberare prelungita - 600 mg
clorură de sodiu 0,9% soluţie perfuzabilă
ncpc international corp. - natrii chloridum - soluţie perfuzabilă - 0,9%
clorură de sodiu 0,9% soluţie perfuzabilă
ncpc international corp. - natrii chloridum - soluţie perfuzabilă - 0,9%